Ceritinib companion diagnostic - NovartisAlternative Names: LDK 378 companion diagnostic - Novartis
Latest Information Update: 25 Sep 2013
At a glance
- Originator Novartis
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Clinical Phase Unknown Non-small cell lung cancer
Most Recent Events
- 08 Nov 2012 Clinical trials in Non-small cell lung cancer (diagnosis) in Japan (unspecified route)
- 08 Nov 2012 Clinical trials in Non-small cell lung cancer (diagnosis) in USA (unspecified route)